SCHEMBL7475165

SCHEMBL7475165

c1ccc(CCc2ccc[nH]2)cc1

nearest known ligand 0.61

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.52
DAO P14920 2/20 0.48
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
CASP1 P29466 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GPR84 Q9NQS5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7714735 0.87 HRH3 (0.55) DAOMAOAMAOBGPR84
SCHEMBL4350635 0.87 HRH3 (0.50) DAOMAOA
SCHEMBL7172295 0.85 MAOA (0.42) DAOMAOA
SCHEMBL17104827 0.85 HRH3 (0.53) DAOMAOAGPR84
SCHEMBL11118375 0.83 LTA4H (0.54) MAOAMAOB
SCHEMBL1108477 0.79 TAAR1 (0.50) TAAR1DAOMAOAHPGD
SCHEMBL11117749 0.77 HRH4 (0.49) ALDH1A1
SCHEMBL9410203 0.76 MAOA (0.41) TAAR1DAOMAOAMAOBALDH1A1
SCHEMBL7003873 0.75 GPR84 (0.41) DAOMAOAGPR84
SCHEMBL9203304 0.75 DAO (0.51) TAAR1DAOMAOAMAOBGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112194629-A Phenethyl azole derivative and preparation method and application thereof 聊城大学 2021-01-08 CN claimed
CN-104203918-B Novel polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the beta2 adrenergic receptor. 阿尔米雷尔有限公司 2017-01-18 CN claimed
CN-112194629-B Phenethyl azole derivative and preparation method and application thereof 聊城大学 2023-10-24 CN disclosed
CN-112194629-B Phenethyl azole derivative and preparation method and application thereof 聊城大学 2023-10-24 CN disclosed
CN-112194629-B Phenethyl azole derivative and preparation method and application thereof 聊城大学 2023-10-24 CN disclosed
US-20220024869-A1 GRP94 SELECTIVE INHIBITORS AND USES THEREOF UNIVERSITY OF KANSAS 2022-01-27 US disclosed
US-10975030-B2 Grp94 selective inhibitors and uses thereof UNIVERSITY OF KANSAS (US) 2021-04-13 US disclosed
CN-112194629-A Phenethyl azole derivative and preparation method and application thereof 聊城大学 2021-01-08 CN disclosed
CN-112194629-A Phenethyl azole derivative and preparation method and application thereof 聊城大学 2021-01-08 CN disclosed
CN-112194629-A Phenethyl azole derivative and preparation method and application thereof 聊城大学 2021-01-08 CN disclosed
US-20200071271-A1 GRP94 SELECTIVE INHIBITORS AND USES THEREOF UNIVERSITY OF SOUTH FLORIDA 2020-03-05 US disclosed
US-9873697-B2 Histone demethylase inhibitors Celgene Quantical Research, Inc. (US) 2018-01-23 US disclosed
US-20170313702-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-11-02 US disclosed
EP-1001933-A4 CASPASES AND APOPTOSIS SMITHKLINE BEECHAM CORP (US) 2002-11-06 EP disclosed
EP-1001933-A1 CASPASES AND APOPTOSIS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-24 EP disclosed
WO-1999006367-A1 CASPASES AND APOPTOSIS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-11 WO disclosed
EP-0611301-A1 CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 1994-08-24 EP disclosed
EP-0611301-A4 CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS. PROCTER & GAMBLE (US) 1993-03-01 EP disclosed
WO-1991016034-A1 CHELATOR COMPOSITIONS COMPRISING OXIME COMPOUNDS THE PROCTER & GAMBLE COMPANY (US) 1991-10-31 WO disclosed
EP-0115413-A1 +/- 2-(Phenethyl)-5-((3,4-methylenedioxy)-alpha-hydroxybenzyl)-pyrrolidines, pharmaceutical compositions containing them, processes for their production and intermediates therefor SYNTEX (U.S.A.) INC. (US) 1984-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313702-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5A TAAR1 4275/4885DAO 2300/4885MAOA 537/4885
US-20200071271-A1 GRP94 SELECTIVE INHIBITORS AND USES THEREOF GRPR, HSP90B1, HSPE1 TAAR1 2540/4885DAO 4189/4885MAOA 4630/4885
US-20220024869-A1 GRP94 SELECTIVE INHIBITORS AND USES THEREOF GRPR, HSP90B1, HSPE1 TAAR1 2540/4885DAO 4189/4885MAOA 4630/4885
US-10975030-B2 Grp94 selective inhibitors and uses thereof GRPR, HSP90B1, HSPE1 TAAR1 2540/4885DAO 4189/4885MAOA 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.